CG Oncology, Inc. cotiza a 62.40 USD y tiene una capitalización bursátil de $5.5B. En los últimos 12 meses ha facturado $6M con un margen de flujo de caja libre del -3279.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cret…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.90 | $-0.71 | $-0.51 |
| Estimado | $-0.82 | $-0.64 | $-0.54 | $-0.58 |
| Sorpresa | — | -40.6% | -31.5% | +12.1% |
| Métrica | CGON | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -4722.1% | -38.6% | -4683.5% |
| Net Margin | -3985.0% | -33.6% | -3951.5% |
| FCF Margin | -3279.2% | -13.9% | -3265.3% |
| ROE | -21.4% | -40.4% | +19.0% |
| ROA | -20.3% | -32.0% | +11.7% |
| Current Ratio | 24.63 | 2.84 | +21.79 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |